JP2018052979A5 - - Google Patents

Download PDF

Info

Publication number
JP2018052979A5
JP2018052979A5 JP2017247931A JP2017247931A JP2018052979A5 JP 2018052979 A5 JP2018052979 A5 JP 2018052979A5 JP 2017247931 A JP2017247931 A JP 2017247931A JP 2017247931 A JP2017247931 A JP 2017247931A JP 2018052979 A5 JP2018052979 A5 JP 2018052979A5
Authority
JP
Japan
Prior art keywords
cancer
composition
monoclonal antibody
abcb5
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017247931A
Other languages
English (en)
Other versions
JP2018052979A (ja
JP6530044B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018052979A publication Critical patent/JP2018052979A/ja
Publication of JP2018052979A5 publication Critical patent/JP2018052979A5/ja
Application granted granted Critical
Publication of JP6530044B2 publication Critical patent/JP6530044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (14)

  1. ＡＢＣＢ５に選択的に結合する単離されたモノクローナル抗体を含む、癌の治療における使用のための組成物であって、該治療は、ＡＢＣＢ５に選択的に結合する該単離されたモノクローナル抗体を、癌を有する被験体に癌の治療に有効な量で送達することを含み、ここで、該単離されたモノクローナル抗体は、化学治療剤の同時投与なしで単独で使用される、組成物。
  2. 前記単離されたモノクローナル抗体が、配列番号５のアミノ酸配列を含むＣＤＲ３−Ｈ３配列を有する免疫グロブリン重鎖可変ドメイン、および配列番号８のアミノ酸配列を含むＣＤＲ３−Ｌ３配列を有する免疫グロブリン軽鎖可変ドメインを含む、請求項１に記載の組成物。
  3. 前記単離されたモノクローナル抗体が、ヒト定常領域を有する、またはヒト定常領域およびヒト可変フレームワーク領域を有する、請求項１に記載の組成物。
  4. 前記単離されたモノクローナル抗体が、ｍＡｂ ３Ｃ２−１Ｄ１２のＡＢＣＢ５への結合を競合的に阻害し、該ｍＡｂ ３Ｃ２−１Ｄ１２は、配列番号１のアミノ酸配列を有する重鎖可変領域および配列番号２のアミノ酸配列を有する軽鎖可変領域からなる、請求項１に記載の組成物。
  5. 前記単離されたモノクローナル抗体が、免疫グロブリンクラスＩｇＡ、ＩｇＧｂ１、ＩｇＧ２、ＩｇＧ３、ＩｇＧ４またはＩｇＭのものである、請求項１に記載の組成物。
  6. 前記単離されたモノクローナル抗体が単一鎖抗体である、請求項１に記載の組成物。
  7. 前記被験体がメラノーマを有する、請求項１に記載の組成物。
  8. 前記被験体がヒト被験体である、請求項１に記載の組成物。
  9. 前記被験体が愛玩動物である、請求項１に記載の組成物。
  10. 前記癌が、ＡＢＣＢ５を発現する癌幹細胞を有する癌であり、胆管癌、脳癌、乳癌、頸癌、絨毛癌、結腸癌、子宮内膜癌、食道癌、胃癌、表皮内新生物、リンパ腫、肝臓癌、肺癌（例えば、小細胞および非小細胞）、神経芽細胞腫、口腔癌、卵巣癌、膵臓癌、前立腺癌、直腸癌、肉腫、皮膚癌、精巣癌、甲状腺癌、および腎臓癌からなる群より選択される、請求項１に記載の組成物。
  11. 前記組成物は、前記被験体におけるＡＢＣＢ５陽性幹細胞の存在の検出後に、該被験体へと送達されることを特徴とする、請求項１に記載の組成物。
  12. 前記ＡＢＣＢ５陽性幹細胞の存在は、被験体からの試料をＡＢＣＢ５に選択的に結合するペプチドと接触させ、該ペプチドに結合する細胞を検出することによって検出される、請求項１１に記載の組成物。
  13. 前記試料が腫瘍塊の試料である、請求項１２に記載の組成物。
  14. ＡＢＣＢ５に選択的に結合する単離されたモノクローナル抗体を含む、癌の治療における使用のための組成物であって、該治療は、ＡＢＣＢ５に選択的に結合する該単離されたモノクローナル抗体を、癌を有する被験体に癌の治療に有効な量で全身送達することを含む、組成物。
JP2017247931A 2007-04-12 2017-12-25 癌療法のためのａｂｃｂ５標的化 Active JP6530044B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92312807P 2007-04-12 2007-04-12
US60/923,128 2007-04-12
US705907P 2007-12-11 2007-12-11
US61/007,059 2007-12-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016153402A Division JP6268237B2 (ja) 2007-04-12 2016-08-04 癌療法のためのａｂｃｂ５標的化

Publications (3)

Publication Number Publication Date
JP2018052979A JP2018052979A (ja) 2018-04-05
JP2018052979A5 true JP2018052979A5 (ja) 2018-05-31
JP6530044B2 JP6530044B2 (ja) 2019-06-12

Family

ID=39661432

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010503072A Active JP5889527B2 (ja) 2007-04-12 2008-04-11 癌療法のためのａｂｃｂ５標的化
JP2014090150A Withdrawn JP2014133770A (ja) 2007-04-12 2014-04-24 癌療法のためのａｂｃｂ５標的化
JP2016153402A Active JP6268237B2 (ja) 2007-04-12 2016-08-04 癌療法のためのａｂｃｂ５標的化
JP2017247931A Active JP6530044B2 (ja) 2007-04-12 2017-12-25 癌療法のためのａｂｃｂ５標的化

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2010503072A Active JP5889527B2 (ja) 2007-04-12 2008-04-11 癌療法のためのａｂｃｂ５標的化
JP2014090150A Withdrawn JP2014133770A (ja) 2007-04-12 2014-04-24 癌療法のためのａｂｃｂ５標的化
JP2016153402A Active JP6268237B2 (ja) 2007-04-12 2016-08-04 癌療法のためのａｂｃｂ５標的化

Country Status (15)

Country Link
US (4) US7928202B2 (ja)
EP (3) EP2155248B1 (ja)
JP (4) JP5889527B2 (ja)
AU (1) AU2008239633B2 (ja)
CA (1) CA2718573C (ja)
CY (2) CY1116823T1 (ja)
DK (2) DK2155248T3 (ja)
ES (2) ES2547016T3 (ja)
HR (2) HRP20150934T1 (ja)
HU (2) HUE027593T2 (ja)
LT (1) LT2644205T (ja)
PL (2) PL2644205T3 (ja)
PT (2) PT2155248E (ja)
SI (2) SI2644205T1 (ja)
WO (1) WO2008127656A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333182A1 (en) * 2000-06-05 2018-06-13 The Brigham and Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
PL2772535T3 (pl) * 2006-05-31 2022-09-05 Children's Medical Center Corporation Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
JP5889527B2 (ja) 2007-04-12 2016-03-22 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌療法のためのａｂｃｂ５標的化
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010056332A1 (en) * 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
US20110280862A1 (en) * 2010-05-14 2011-11-17 The University Of Hong Kong Gep and drug transporter regulation, cancer therapy and prognosis
EP2964238B1 (en) 2013-02-19 2021-01-13 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
ES2892403T3 (es) 2013-05-10 2022-02-04 Childrens Medical Center Curación de heridas e ingeniería de tejidos
US9177410B2 (en) 2013-08-09 2015-11-03 Ayla Mandel System and method for creating avatars or animated sequences using human body features extracted from a still image
WO2016179576A1 (en) * 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
MX2018000619A (es) 2015-07-16 2019-03-06 Bioxcel Therapeutics Inc Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
SG11202010260XA (en) * 2018-04-25 2020-11-27 Childrens Medical Center Abcb5 ligands and substrates
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
WO2021211761A1 (en) * 2020-04-15 2021-10-21 Children's Medical Center Corporation Targeting abcb5 in glioblastoma multiforme
JP2023524102A (ja) * 2020-04-30 2023-06-08 ザ チルドレンズ メディカル センター コーポレーション Ａｂｃｂ５に特異的な抗体およびその使用
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565354A (en) 1896-08-04 James h
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
WO1980001139A1 (en) 1978-12-06 1980-06-12 Svedman Paul Device for treating tissues,for example skin
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
AT379688B (de) 1982-11-22 1986-02-10 List Hans Sensorelement zur bestimmung des o2-gehaltes einer probe
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0174810B1 (en) 1984-09-10 1993-07-21 HSC Research Development Corporation Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
GB8509978D0 (en) 1985-04-18 1985-05-30 Juhasz L Wound dressings
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5565354A (en) 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5399483A (en) 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5434075A (en) 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6436078B1 (en) 1994-12-06 2002-08-20 Pal Svedman Transdermal perfusion of fluids
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
GB2272645B8 (en) 1992-11-23 2010-02-10 Johnson & Johnson Medical Wound dressing
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
WO1995018972A1 (en) 1994-01-05 1995-07-13 Arqule, Inc. Systematic modular production of aminimide- and oxazolone-based molecules having selected properties
GB9403135D0 (en) 1994-02-18 1994-04-06 Univ Glasgow Wound healing device
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP3403416B2 (ja) * 1996-06-28 2003-05-06 松下電工株式会社 改質装置
US5904659A (en) 1997-02-14 1999-05-18 Exogen, Inc. Ultrasonic treatment for wounds
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
DE19722075C1 (de) 1997-05-27 1998-10-01 Wilhelm Dr Med Fleischmann Vorrichtung zur Applikation von Wirkstoffen an einer Wundoberfläche
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
US6071267A (en) 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB9808836D0 (en) 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
JP4220058B2 (ja) 1998-06-30 2009-02-04 浜松ホトニクス株式会社 半導体位置検出器
US6479072B1 (en) 1999-02-11 2002-11-12 The General Hospital Corporation Microfabricated membranes and matrices
US6277574B1 (en) * 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney
US6755807B2 (en) 1999-11-29 2004-06-29 Hill-Rom Services, Inc. Wound treatment apparatus
EP2345742B1 (en) 2000-03-30 2014-06-11 The Whitehead Institute for Biomedical Research RNA sequence-specific mediators of RNA interference
EP3333182A1 (en) 2000-06-05 2018-06-13 The Brigham and Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
AU2001268328A1 (en) * 2000-06-12 2001-12-24 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
DE60140252D1 (de) 2000-06-22 2009-12-03 Genentech Inc Agonistische monoklonale antikörper gegen trkc
WO2002029106A2 (en) 2000-10-03 2002-04-11 California Institute Of Technology Microfluidic devices and methods of use
EP1412387A2 (en) 2000-10-27 2004-04-28 Incyte Genomics, Inc. Transporters and ion channels
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US6685681B2 (en) 2000-11-29 2004-02-03 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US8015677B2 (en) 2000-12-01 2011-09-13 Aard-Balm Limited Embalming fluid
WO2002053290A2 (en) 2001-01-08 2002-07-11 President And Fellows Of Harvard College Valves and pumps for microfluidic systems and method for making microfluidic systems
WO2002062968A2 (en) 2001-02-02 2002-08-15 The Regents Of The University Of Michigan Micro-tubular materials and cell constructs
WO2002083046A1 (en) 2001-04-16 2002-10-24 Pamela Howard Wound dressing system
AU2002359828A1 (en) 2001-12-26 2003-07-24 Hill-Rom Services Inc. Vented vacuum bandage and method
AU2002359830A1 (en) 2001-12-26 2003-07-24 Hill-Rom Services, Inc. Wound vacuum therapy dressing kit
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
PT2206517T (pt) 2002-07-03 2023-11-07 Tasuku Honjo Composições de imunopotenciação contendo anticorpos anti-pd-l1
ES2539627T3 (es) 2002-11-07 2015-07-02 Immunogen, Inc. Anticuerpos anti-CD33 y método para el tratamiento de leucemia mieloide aguda usando los mismos
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0325130D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with scaffold
EP1702061A4 (en) 2003-11-24 2007-05-02 Univ Rockefeller METHOD FOR ISOLATING A SLOW CYCLE, PLURIPOTENT CELL, REGENERATING SPONTANEOUSLY
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
WO2005079257A2 (en) 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
CA3218940A1 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2612021A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
PL2772535T3 (pl) 2006-05-31 2022-09-05 Children's Medical Center Corporation Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
EP2079484A4 (en) 2006-09-07 2010-03-17 Stemline Therapeutics Inc MONITORING OF CANCER STEM CELLS
JP5889527B2 (ja) 2007-04-12 2016-03-22 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌療法のためのａｂｃｂ５標的化
WO2010056332A1 (en) 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
EP2964238B1 (en) 2013-02-19 2021-01-13 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
ES2892403T3 (es) 2013-05-10 2022-02-04 Childrens Medical Center Curación de heridas e ingeniería de tejidos

Similar Documents

Publication Publication Date Title
JP2018052979A5 (ja)
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
CY1120359T1 (el) Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες
MA42935B1 (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
JP2015533788A5 (ja)
JP2020501532A5 (ja)
JP2013166763A5 (ja)
NZ701444A (en) Antibodies to matrix metalloproteinase 9
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
TR201815254T4 (tr) Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
EA201190116A1 (ru) Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
WO2010005566A3 (en) Notch-binding agents and antagonists and methods of use thereof
WO2012135854A3 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
WO2017060322A3 (en) Ptefb-inhibitor-adc
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
EA201400390A1 (ru) Антитела к tl1a и их применение
EP3782645A4 (en) CANCER T LYMPHOCYTE THERAPY PRODUCT ASSISTING COMPOSITION COMPRISING AN ANTI-CD4 MONOCLONAL ANTIBODY INDUCING CD4+ LYMPHOCYTE DEPLETION AND USE THEREOF
JP2014223083A5 (ja)
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
EA200901421A1 (ru) Антитела к il-25
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
JP2017518260A5 (ja)
JP2020516305A5 (ja)